Skip to main content
Top

Open Access 27-04-2024 | Opioids | REVIEW

The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder

Authors: Kelvin Le, Khang Duy Ricky Le, Johnny Nguyen, Jean Hua, Sarah Munday

Published in: Pain and Therapy

Login to get access

Abstract

This narrative review explores current insights into the potential use of medicinal cannabis-related products as an emerging therapy for opioid use disorder in the landscape of increasing knowledge about medicinal cannabis-based products, commercialisation and global legalisation. Preclinical studies have provided preliminary insight into the putative neurobiological mechanisms that underpin the potential for medicinal cannabis to be considered a therapeutic in opioid use disorder and addiction. With the progressive legalisation of cannabis in many jurisdictions worldwide, contemporary research has highlighted further evidence that medicinal cannabis may have efficacy in reducing cravings and withdrawal effects, and therefore may be considered as an adjunct or standalone to current medications for opioid use disorder. Despite this potential, the landscape of research in this space draws from a large number of observational studies, with a paucity of rigorous randomised controlled trials to ascertain a true understanding of effect size and safety profile. With current challenges in implementation that arise from political and legal qualms about adopting medicinal cannabis on the background of associated social stigma, significant hurdles remain to be addressed by government, policy-makers, healthcare providers and researchers before medical cannabis can be introduced globally for the treatment of opioid use disorder.
Literature
1.
go back to reference Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555–604.PubMedPubMedCentralCrossRef Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555–604.PubMedPubMedCentralCrossRef
2.
go back to reference Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid prescribing trends and geographical variation in England, 1998–2018: a retrospective database study. Lancet Psychiatry. 2019;6(2):140–50.PubMedCrossRef Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid prescribing trends and geographical variation in England, 1998–2018: a retrospective database study. Lancet Psychiatry. 2019;6(2):140–50.PubMedCrossRef
3.
go back to reference Larance B, Degenhardt L, Peacock A, et al. Pharmaceutical opioid use and harm in Australia: the need for proactive and preventative responses. Drug Alcohol Rev. 2018;37:S203–5.PubMedCrossRef Larance B, Degenhardt L, Peacock A, et al. Pharmaceutical opioid use and harm in Australia: the need for proactive and preventative responses. Drug Alcohol Rev. 2018;37:S203–5.PubMedCrossRef
6.
go back to reference Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatric Serv (Washington, DC). 2014;65(2):146–57.CrossRef Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatric Serv (Washington, DC). 2014;65(2):146–57.CrossRef
7.
go back to reference Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:Cd002207. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:Cd002207.
8.
go back to reference Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.PubMedPubMedCentralCrossRef Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.PubMedPubMedCentralCrossRef
9.
go back to reference Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: a prospective cohort study among users of illicit substances. Addict Behav. 2019;90:222–8.PubMedCrossRef Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: a prospective cohort study among users of illicit substances. Addict Behav. 2019;90:222–8.PubMedCrossRef
10.
go back to reference Morgan JR, Walley AY, Murphy SM, et al. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021;225: 108764.PubMedPubMedCentralCrossRef Morgan JR, Walley AY, Murphy SM, et al. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021;225: 108764.PubMedPubMedCentralCrossRef
12.
go back to reference Edinoff AN, Wu NW, Nix CA, et al. Historical pathways for opioid addiction, withdrawal with traditional and alternative treatment options with ketamine, cannabinoids, and noribogaine: a narrative review. Health Psychol Res. 2022;10(4):38672. https://doi.org/10.52965/001c.38672. Edinoff AN, Wu NW, Nix CA, et al. Historical pathways for opioid addiction, withdrawal with traditional and alternative treatment options with ketamine, cannabinoids, and noribogaine: a narrative review. Health Psychol Res. 2022;10(4):38672. https://​doi.​org/​10.​52965/​001c.​38672.
13.
go back to reference Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):1–11.CrossRef Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):1–11.CrossRef
14.
go back to reference Gharbi KA, Bonomo YA, Hallinan CM. Evidence from human studies for utilising cannabinoids for the treatment of substance-use disorders: a scoping review with a systematic approach. Int J Environ Res Public Health. 2023;20(5):4087.PubMedPubMedCentralCrossRef Gharbi KA, Bonomo YA, Hallinan CM. Evidence from human studies for utilising cannabinoids for the treatment of substance-use disorders: a scoping review with a systematic approach. Int J Environ Res Public Health. 2023;20(5):4087.PubMedPubMedCentralCrossRef
15.
go back to reference Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174(10):1668–73.PubMedPubMedCentralCrossRef Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174(10):1668–73.PubMedPubMedCentralCrossRef
17.
go back to reference Reed K, Day E, Keen J, Strang J. Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother. 2015;16(3):325–33.PubMedCrossRef Reed K, Day E, Keen J, Strang J. Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother. 2015;16(3):325–33.PubMedCrossRef
21.
go back to reference Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N. National guidelines for medication-assisted treatment of opioid dependence. Canberra: Commonwealth of Australia; 2014. p. 38–9. Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N. National guidelines for medication-assisted treatment of opioid dependence. Canberra: Commonwealth of Australia; 2014. p. 38–9.
22.
go back to reference Fareed A, Vayalapalli S, Casarella J, Amar R, Drexler K. Heroin anticraving medications: a systematic review. Am J Drug Alcohol Abuse. 2010;36(6):332–41.PubMedCrossRef Fareed A, Vayalapalli S, Casarella J, Amar R, Drexler K. Heroin anticraving medications: a systematic review. Am J Drug Alcohol Abuse. 2010;36(6):332–41.PubMedCrossRef
24.
go back to reference Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
25.
go back to reference Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016;164:143–50.PubMedPubMedCentralCrossRef Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016;164:143–50.PubMedPubMedCentralCrossRef
26.
go back to reference Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(Suppl 1):S5-s25.PubMedPubMedCentralCrossRef Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(Suppl 1):S5-s25.PubMedPubMedCentralCrossRef
27.
go back to reference Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26–30.PubMedPubMedCentralCrossRef Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26–30.PubMedPubMedCentralCrossRef
28.
go back to reference Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107(3–4):131–49.PubMedCrossRef Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107(3–4):131–49.PubMedCrossRef
29.
go back to reference Chye Y, Christensen E, Solowij N, Yücel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10:63.PubMedPubMedCentralCrossRef Chye Y, Christensen E, Solowij N, Yücel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10:63.PubMedPubMedCentralCrossRef
30.
go back to reference Manzanares J, Cabanero D, Puente N, García-Gutiérrez MS, Grandes P, Maldonado R. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol. 2018;157:108–21.PubMedCrossRef Manzanares J, Cabanero D, Puente N, García-Gutiérrez MS, Grandes P, Maldonado R. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol. 2018;157:108–21.PubMedCrossRef
32.
33.
go back to reference Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282–98.PubMedCrossRef Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282–98.PubMedCrossRef
34.
go back to reference Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637–54.PubMedCrossRef Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637–54.PubMedCrossRef
35.
go back to reference De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160(1):136.PubMedCrossRef De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160(1):136.PubMedCrossRef
36.
go back to reference Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020;24:1–6.CrossRef Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020;24:1–6.CrossRef
37.
go back to reference Shover CL, Vest NA, Chen D, et al. Association of state policies allowing medical cannabis for opioid use disorder with dispensary marketing for this indication. JAMA Netw Open. 2020;3(7):e2010001-e.CrossRef Shover CL, Vest NA, Chen D, et al. Association of state policies allowing medical cannabis for opioid use disorder with dispensary marketing for this indication. JAMA Netw Open. 2020;3(7):e2010001-e.CrossRef
38.
go back to reference Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharmacol Exp Ther. 2019;371(2):422–52.PubMedPubMedCentralCrossRef Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharmacol Exp Ther. 2019;371(2):422–52.PubMedPubMedCentralCrossRef
39.
go back to reference Birch EA. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet. 1889;1(625):25. Birch EA. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. Lancet. 1889;1(625):25.
40.
go back to reference Meacham MC, Nobles AL, Tompkins DA, Thrul J. “I got a bunch of weed to help me through the withdrawals”: naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. PLoS One. 2022;17(2): e0263583.PubMedPubMedCentralCrossRef Meacham MC, Nobles AL, Tompkins DA, Thrul J. “I got a bunch of weed to help me through the withdrawals”: naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. PLoS One. 2022;17(2): e0263583.PubMedPubMedCentralCrossRef
41.
go back to reference Rosic T, Kapoor R, Panesar B, et al. The association between cannabis use and outcome in pharmacological treatment for opioid use disorder. Harm Reduct J. 2021;18(1):24.PubMedPubMedCentralCrossRef Rosic T, Kapoor R, Panesar B, et al. The association between cannabis use and outcome in pharmacological treatment for opioid use disorder. Harm Reduct J. 2021;18(1):24.PubMedPubMedCentralCrossRef
42.
go back to reference Bisaga A, Sullivan MA, Glass A, et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015;154:38–45.PubMedPubMedCentralCrossRef Bisaga A, Sullivan MA, Glass A, et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015;154:38–45.PubMedPubMedCentralCrossRef
43.
go back to reference Socías ME, Wood E, Lake S, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250–8.PubMedPubMedCentralCrossRef Socías ME, Wood E, Lake S, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250–8.PubMedPubMedCentralCrossRef
44.
go back to reference Epstein DH, Preston KL. No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. Am J Addict. 2015;24(4):323–8.PubMedPubMedCentralCrossRef Epstein DH, Preston KL. No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. Am J Addict. 2015;24(4):323–8.PubMedPubMedCentralCrossRef
45.
go back to reference Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol. 2005;10(2):165–9.PubMedCrossRef Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol. 2005;10(2):165–9.PubMedCrossRef
46.
47.
go back to reference Henderson LA, Kotsirilos V, Cairns EA, Ramachandran A, Peck CC, McGregor IS. Medicinal cannabis in the treatment of chronic pain. Aust J General Pract. 2021;50(10):724–32.CrossRef Henderson LA, Kotsirilos V, Cairns EA, Ramachandran A, Peck CC, McGregor IS. Medicinal cannabis in the treatment of chronic pain. Aust J General Pract. 2021;50(10):724–32.CrossRef
48.
go back to reference National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington DC: National Academies Press; 2017. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington DC: National Academies Press; 2017.
49.
go back to reference Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2(1):160–6.PubMedPubMedCentralCrossRef Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2(1):160–6.PubMedPubMedCentralCrossRef
50.
go back to reference Schlag AK, O’Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021;191:108586.PubMedCrossRef Schlag AK, O’Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021;191:108586.PubMedCrossRef
51.
go back to reference Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–44.PubMedCrossRef Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–44.PubMedCrossRef
52.
go back to reference Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.PubMedCrossRef Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.PubMedCrossRef
53.
go back to reference McCarty D. Does medical cannabis reduce use of prescription opioids? Am J Psychiatry 2018;176(1):6–7. McCarty D. Does medical cannabis reduce use of prescription opioids? Am J Psychiatry 2018;176(1):6–7.
54.
go back to reference Liang D, Bao Y, Wallace M, Grant I, Shi Y. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993–2014. Addiction. 2018;113(11):2060–70.PubMedPubMedCentralCrossRef Liang D, Bao Y, Wallace M, Grant I, Shi Y. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993–2014. Addiction. 2018;113(11):2060–70.PubMedPubMedCentralCrossRef
55.
go back to reference Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood). 2016;35(7):1230–6.PubMedCrossRef Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood). 2016;35(7):1230–6.PubMedCrossRef
57.
go back to reference Olfson M, Wall MM, Liu S-M, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2018;175(1):47–53.PubMedCrossRef Olfson M, Wall MM, Liu S-M, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2018;175(1):47–53.PubMedCrossRef
58.
go back to reference Elkrief L, Bastien G, McAnulty C, et al. Differential effect of cannabis use on opioid agonist treatment outcomes: exploratory analyses from the OPTIMA study. J Substance Use Addict Treatment. 2023;149: 209031.CrossRef Elkrief L, Bastien G, McAnulty C, et al. Differential effect of cannabis use on opioid agonist treatment outcomes: exploratory analyses from the OPTIMA study. J Substance Use Addict Treatment. 2023;149: 209031.CrossRef
59.
go back to reference Raby WN, Carpenter KM, Rothenberg J, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18(4):301–8.PubMedPubMedCentralCrossRef Raby WN, Carpenter KM, Rothenberg J, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18(4):301–8.PubMedPubMedCentralCrossRef
60.
go back to reference Lake S, Buxton J, Walsh Z, et al. Methadone dose, cannabis use, and treatment retention: findings from a community-based sample of people who use unregulated drugs. J Addict Med. 2023;17(1):e18–26.PubMedCrossRef Lake S, Buxton J, Walsh Z, et al. Methadone dose, cannabis use, and treatment retention: findings from a community-based sample of people who use unregulated drugs. J Addict Med. 2023;17(1):e18–26.PubMedCrossRef
61.
go back to reference Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, Walsh SL. Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend. 2015;157:179–83.PubMedPubMedCentralCrossRef Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, Walsh SL. Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend. 2015;157:179–83.PubMedPubMedCentralCrossRef
62.
go back to reference De Aquino JP, Meyerovich J, Xie CZ, et al. Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: a within-subject, randomized, placebo-controlled laboratory study. Addict Biol. 2023;28(9):e13317.PubMedCrossRef De Aquino JP, Meyerovich J, Xie CZ, et al. Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: a within-subject, randomized, placebo-controlled laboratory study. Addict Biol. 2023;28(9):e13317.PubMedCrossRef
63.
go back to reference Kudrich C, Hurd YL, Salsitz E, Wang A-L. Adjunctive management of opioid withdrawal with the nonopioid medication cannabidiol. Cannabis Cannabinoid Res. 2022;7(5):569–81.PubMedPubMedCentralCrossRef Kudrich C, Hurd YL, Salsitz E, Wang A-L. Adjunctive management of opioid withdrawal with the nonopioid medication cannabidiol. Cannabis Cannabinoid Res. 2022;7(5):569–81.PubMedPubMedCentralCrossRef
64.
go back to reference Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020;22(3):241–50.PubMedPubMedCentralCrossRef Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020;22(3):241–50.PubMedPubMedCentralCrossRef
65.
go back to reference Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol effect on cue-induced craving for individuals with opioid use disorder treated with buprenorphine: a small proof-of-concept open-label study. Integrat Med Rep. 2022;1(1):157–63.CrossRef Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol effect on cue-induced craving for individuals with opioid use disorder treated with buprenorphine: a small proof-of-concept open-label study. Integrat Med Rep. 2022;1(1):157–63.CrossRef
66.
go back to reference Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of cannabidiol in the therapeutic intervention for substance use disorders. Front Pharmacol. 2021;12:626010.PubMedPubMedCentralCrossRef Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of cannabidiol in the therapeutic intervention for substance use disorders. Front Pharmacol. 2021;12:626010.PubMedPubMedCentralCrossRef
67.
go back to reference Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol. 2013;18(2):286–96.PubMedCrossRef Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol. 2013;18(2):286–96.PubMedCrossRef
68.
go back to reference Paulus V, Billieux J, Benyamina A, Karila L. Cannabidiol in the context of substance use disorder treatment: a systematic review. Addict Behav. 2022;132:107360. Paulus V, Billieux J, Benyamina A, Karila L. Cannabidiol in the context of substance use disorder treatment: a systematic review. Addict Behav. 2022;132:107360.
69.
go back to reference Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911–22.PubMedCrossRef Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911–22.PubMedCrossRef
70.
go back to reference Suzuki J, Prostko S, Szpak V, et al. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: a pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023;14:1155984.PubMedPubMedCentralCrossRef Suzuki J, Prostko S, Szpak V, et al. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: a pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023;14:1155984.PubMedPubMedCentralCrossRef
71.
go back to reference Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046–55.PubMedPubMedCentralCrossRef Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046–55.PubMedPubMedCentralCrossRef
72.
go back to reference Rodriguez-Arias M, Aguilar MA, Minarro J. Therapies in early development for the treatment of opiate addiction. Expert Opin Investig Drugs. 2015;24(11):1459–72.PubMedCrossRef Rodriguez-Arias M, Aguilar MA, Minarro J. Therapies in early development for the treatment of opiate addiction. Expert Opin Investig Drugs. 2015;24(11):1459–72.PubMedCrossRef
73.
go back to reference Fallon MT, Albert Lux E, McQuade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119–33.PubMedPubMedCentralCrossRef Fallon MT, Albert Lux E, McQuade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119–33.PubMedPubMedCentralCrossRef
74.
go back to reference Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254–64.PubMedCrossRef Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254–64.PubMedCrossRef
75.
go back to reference Dunn KE, Bergeria CL, Huhn AS, et al. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology. 2021;46(8):1451–9.PubMedPubMedCentralCrossRef Dunn KE, Bergeria CL, Huhn AS, et al. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology. 2021;46(8):1451–9.PubMedPubMedCentralCrossRef
76.
go back to reference Babalonis S, Lofwall MR, Sloan PA, Nuzzo PA, Fanucchi LC, Walsh SL. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. Psychopharmacology. 2019;236(11):3341–52.PubMedPubMedCentralCrossRef Babalonis S, Lofwall MR, Sloan PA, Nuzzo PA, Fanucchi LC, Walsh SL. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. Psychopharmacology. 2019;236(11):3341–52.PubMedPubMedCentralCrossRef
77.
go back to reference Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105(1):79–88.PubMedCrossRef Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105(1):79–88.PubMedCrossRef
78.
go back to reference Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390–402.PubMedCrossRef Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390–402.PubMedCrossRef
79.
go back to reference Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56–61.PubMedCrossRef Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56–61.PubMedCrossRef
80.
go back to reference Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370–5.PubMedCrossRef Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370–5.PubMedCrossRef
81.
go back to reference Lucas P. Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduct J. 2017;14:1–6.CrossRef Lucas P. Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduct J. 2017;14:1–6.CrossRef
82.
go back to reference Tormohlen KN, Bicket MC, White S, et al. The state of the evidence on the association between state cannabis laws and opioid-related outcomes: a review. Curr Addict Reports. 2021;8(4):538-45. Tormohlen KN, Bicket MC, White S, et al. The state of the evidence on the association between state cannabis laws and opioid-related outcomes: a review. Curr Addict Reports. 2021;8(4):538-45.
83.
go back to reference Aharonovich E, Liu X, Samet S, Nunes E, Waxman R, Hasin D. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am J Psychiatry. 2005;162(8):1507–14.PubMedCrossRef Aharonovich E, Liu X, Samet S, Nunes E, Waxman R, Hasin D. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am J Psychiatry. 2005;162(8):1507–14.PubMedCrossRef
84.
go back to reference Epstein DH. Cannabidiol: not a cure-all, but a candidate for coping with cue-induced craving. Am J Psychiatry; 2019;176(11):888-91. Epstein DH. Cannabidiol: not a cure-all, but a candidate for coping with cue-induced craving. Am J Psychiatry; 2019;176(11):888-91.
85.
go back to reference De Aquino JP, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: a systematic review of observational and experimental human studies. Drug Alcohol Depend. 2022;241:109702.PubMedPubMedCentralCrossRef De Aquino JP, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: a systematic review of observational and experimental human studies. Drug Alcohol Depend. 2022;241:109702.PubMedPubMedCentralCrossRef
86.
go back to reference Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.PubMedPubMedCentralCrossRef Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.PubMedPubMedCentralCrossRef
87.
go back to reference Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer AF, Manzoni O, Haghparast A. Cannabidiol and substance use disorder: dream or reality. Neuropharmacology. 2022;207:108948. Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer AF, Manzoni O, Haghparast A. Cannabidiol and substance use disorder: dream or reality. Neuropharmacology. 2022;207:108948.
88.
go back to reference Donnelly J, Young M, Marshall B, Hecht ML, Saldutti E. Public health implications of cannabis legalization: an exploration of adolescent use and evidence-based interventions. Int J Environ Res Public Health. 2022;19(6):3336.PubMedPubMedCentralCrossRef Donnelly J, Young M, Marshall B, Hecht ML, Saldutti E. Public health implications of cannabis legalization: an exploration of adolescent use and evidence-based interventions. Int J Environ Res Public Health. 2022;19(6):3336.PubMedPubMedCentralCrossRef
89.
go back to reference Liang D, Wallace MS, Shi Y. Medical and non-medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching. Drug Alcohol Rev. 2019;38(6):597–605.PubMedPubMedCentralCrossRef Liang D, Wallace MS, Shi Y. Medical and non-medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching. Drug Alcohol Rev. 2019;38(6):597–605.PubMedPubMedCentralCrossRef
90.
go back to reference Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav. 2020;199: 173059.PubMedPubMedCentralCrossRef Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav. 2020;199: 173059.PubMedPubMedCentralCrossRef
91.
go back to reference Larkin PJ Jr, Madras BK. Opioids, overdoses, and cannabis: is marijuana an effective therapeutic response to the opioid abuse epidemic. Geo. J.L. & Pub. Pol'y. 2019;17(2):555. Larkin PJ Jr, Madras BK. Opioids, overdoses, and cannabis: is marijuana an effective therapeutic response to the opioid abuse epidemic. Geo. J.L. & Pub. Pol'y. 2019;17(2):555.
94.
95.
go back to reference Schwartz MK, Connery H. Cannabis legislation and substance use disorder treatment. Am J Addict. 2019;28(2):127–9.PubMedCrossRef Schwartz MK, Connery H. Cannabis legislation and substance use disorder treatment. Am J Addict. 2019;28(2):127–9.PubMedCrossRef
96.
go back to reference Piomelli D, Solomon R, Abrams D, et al. Regulatory barriers to research on cannabis and cannabinoids: a proposed path forward. Cannabis Cannabinoid Res. 2019;4(1):21–32.PubMedPubMedCentralCrossRef Piomelli D, Solomon R, Abrams D, et al. Regulatory barriers to research on cannabis and cannabinoids: a proposed path forward. Cannabis Cannabinoid Res. 2019;4(1):21–32.PubMedPubMedCentralCrossRef
Metadata
Title
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder
Authors
Kelvin Le
Khang Duy Ricky Le
Johnny Nguyen
Jean Hua
Sarah Munday
Publication date
27-04-2024
Publisher
Springer Healthcare
Published in
Pain and Therapy
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-024-00599-1
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.